Astrocyte Pharmaceuticals has a total of 49 patents globally, out of which 12 have been granted. Of these 49 patents, more than 89% patents are active. The United States of America is where Astrocyte Pharmaceuticals has filed the maximum number of patents, followed by Japan, South Korea, China and Israel. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Astrocyte Pharmaceuticals.
Astrocyte Pharmaceuticals was founded in 2014. Astrocyte Pharmaceuticals is a clinical-stage therapeutic discovery and development firm focused to improving the rehabilitation and well-being of brain injury patients. Astrocyte is dedicated to developing ground-breaking therapeutic agents for the treatment of brain injury caused by stroke, traumatic brain injury (TBI), concussions and neurodegenerative diseases like Alzheimer’s disease.
Do read about some of the most popular patents of Astrocyte Pharmaceuticals which have been covered by us in this article and also you can find Astrocyte Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Astrocyte Pharmaceuticals patent portfolio.
How many patents does Astrocyte Pharmaceuticals have?
Astrocyte Pharmaceuticals has a total of 49 patents globally. These patents belong to 5 unique patent families. Out of 49 patents, 44 patents are active.
How Many Patents did Astrocyte Pharmaceuticals File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Astrocyte Pharmaceuticals Applications Filed | Astrocyte Pharmaceuticals Patents Granted |
| 2023 | 1 | 2 |
| 2022 | 5 | 6 |
| 2021 | 5 | 1 |
| 2020 | 1 | 1 |
| 2019 | 19 | 1 |
| 2018 | 3 | – |
| 2017 | 15 | 1 |
How many Astrocyte Pharmaceuticals patents are Alive/Dead?
Worldwide Patents
How Many Patents did Astrocyte Pharmaceuticals File in Different Countries?
Countries in which Astrocyte Pharmaceuticals Filed Patents
| Country | Patent |
| United States of America | 9 |
| Japan | 4 |
| Korea (South) | 4 |
| China | 4 |
| Israel | 4 |
| Europe | 3 |
| Hong Kong (S.A.R.) | 3 |
| Australia | 3 |
| Canada | 3 |
| Brazil | 2 |
| South Africa | 2 |
| Mexico | 2 |
| India | 1 |
Where are Research Centers of Astrocyte Pharmaceuticals Patents Located?
The Research Center for Astrocyte Pharmaceuticals is the United States of America.
Best Astrocyte Pharmaceuticals Patent
US9789131B1 is the most popular patent in the Astrocyte Pharmaceuticals portfolio. It has received 12 citations so far from companies like Primetime Life Sciences, Llc.
What Percentage of Astrocyte Pharmaceuticals US Patent Applications Were Granted?
Astrocyte Pharmaceuticals (Excluding its subsidiaries) has filed 8 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 6 have been granted leading to a grant rate of 100%.
Below are the key stats of Enterin patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Astrocyte Pharmaceuticals?
| Law Firm | Total Applications | Success Rate |
| Dechert Llp | 8 | 100% |
List of Astrocyte Pharmaceuticals patents
| Astrocyte Pharmaceuticals Patents | Title |
| US11484545B2 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| US11324769B2 | Polymorphic Compounds And Uses Thereof |
| US10953031B2 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| US10765693B2 | Polymorphic Compounds And Uses Thereof |
| US10265338B2 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| US9789131B1 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| US20230165887A1 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| US20220305044A1 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| US20210030760A1 | Compounds And Methods For Treating Addiction And Related Disorders |
| EP3856741A4 | Polymorphic Compounds And Uses Thereof |
| EP3749322A4 | Compounds And Methods For Treating Addiction And Related Disorders |
| EP3445368A4 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| CN109310695B | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| CN114903903A | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| CN112930349A | Polymorphic Compounds And Uses Thereof |
| CN112218638A | Compounds And Methods For Treating Addiction And Related Disorders |
| WO2023091791A1 | Methods Of Treating Neurological And Cardiovascular Conditions |
| CA3113250A1 | Polymorphic Compounds And Uses Thereof |
| CA3126600A1 | Compounds And Methods For Treating Addiction And Related Disorders |
| CA3020490A1 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| JP7311855B2 | Compounds And Methods For Treating Addiction And Related Disorders |
| JP7109005B2 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| JP2022088642A5 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| JP2022502405A5 | Polymorphic Compounds And Uses Thereof |
| AU2017254720B2 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| AU2023202694A1 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| AU2019346585A1 | Polymorphic Compounds And Uses Thereof |
| HK40058352A | Polymorphic Compounds And Uses Thereof |
| HK40042287A | Compounds And Methods For Treating Addiction And Related Disorders |
| HK40004057A | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| MX391725B | Compounds And Methods For Treatment Of Neurological And Cardiovascular Conditions. |
| MX2021003515A | Polymorphic Compounds And Uses Thereof. |
| KR102445887B1 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| KR1020220132042A | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| IL289423A | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| KR1020210093864A | Polymorphic Compounds And Uses Thereof |
| BR112021005290A2 | Polymorphic Compounds And Uses Thereof |
| IL281718A | Polymorphic Compounds And Uses Thereof |
| ZA202101883A | Polymorphic Compounds And Uses Thereof |
| KR1020200138197A | Compounds And Methods For Treating Addiction And Related Disorders |
| IL276358A | Compounds And Methods For Treating Addiction And Related Disorders |
| BR112018071560A2 | Compounds And Methods To Treat Neurological And Cardiovascular Conditions |
| IL262487A | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| ZA201806713A | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| WO2022232810A1 | Purine Nucleosides, Their Intermediates, And Methods Of Preparation Thereof |
| WO2020069068A9 | Polymorphic Compounds And Uses Thereof |
| WO2019157317A1 | Compounds And Methods For Treating Addiction And Related Disorders |
| WO2017185061A1 | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
| IN201817040537A | Compounds And Methods For Treating Neurological And Cardiovascular Conditions |
What are Astrocyte Pharmaceuticals key innovation segments?
What Technologies are Covered by Astrocyte Pharmaceuticals?
The chart below distributes patents filed by Astrocyte Pharmaceuticals